$2.79
0.145.28%
Ult. Agg.: Nov 6, 6:40 PM
ARS Pharmaceuticals (SPRY) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.36 | $-0.33 | -9.09 % |
| Q2 | Aug 13, 2026 | $-0.63 | $-0.50 | -26.0 % |
| Q1 | May 15, 2026 | $-0.61 | $-0.53 | -15.1 % |
| Q4 | Mar 9, 2026 | $-0.42 | $-0.46 | 8.70 % |
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.33 | $-0.50 | $-0.53 | $-0.46 |
| Actual | $-0.36 | $-0.63 | $-0.61 | $-0.42 |
| Surprise | -9.09% | -26.0% | -15.1% | +8.70% |
| Revenue | ||||
| Estimate | $42.1M | $31.4M | $22.1M | $25.6M |
| Actual | $37.7M | $33.7M | $22.7M | $28.1M |
| Surprise | -10.5% | +7.07% | +2.44% | +9.52% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.27 | $-0.38 | $-0.21 | $-0.07 |
| Revenue | ||||
| Consensus | $30.7M | $27.7M | — | — |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $37.71M | $42.13M | -10.5 % |
| Q2 | Aug 13, 2026 | $33.66M | $31.43M | 7.07 % |
| Q1 | May 15, 2026 | $22.68M | $22.14M | 2.44 % |
| Q4 | Mar 9, 2026 | $28.09M | $25.65M | 9.52 % |